168 related articles for article (PubMed ID: 9445356)
1. Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators.
Serebruany VL; Gurbel PA; Shustov AR; Dalesandro MR; Gumbs CI; Grabletz LB; Bahr RD; Ohman EM; Topol EJ
Stroke; 1998 Jan; 29(1):235-8. PubMed ID: 9445356
[TBL] [Abstract][Full Text] [Related]
2. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries.
Gurbel PA; Serebruany VL; Shustov AR; Bahr RD; Carpo C; Ohman EM; Topol EJ
J Am Coll Cardiol; 1998 Jun; 31(7):1466-73. PubMed ID: 9626821
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction.
Serebruany VL; Gurbel PA; Shustov AR; Ohman EM; Topol EJ
Am Heart J; 1998 Sep; 136(3):398-405. PubMed ID: 9736129
[TBL] [Abstract][Full Text] [Related]
4. Baseline platelet aggregation and major receptor expression predict subsequent activity following thrombolysis for acute myocardial infarction.
Gurbel PA; Kereiakes DJ; Atar D; Serebruany VL
Scand Cardiovasc J; 2000; 34(1):53-8. PubMed ID: 10816061
[TBL] [Abstract][Full Text] [Related]
5. Antecedent aspirin therapy inhibits baseline platelet activity in patients presenting with acute myocardial infarction. The GUSTO-III Platelet Substudy.
Serebruany VL; Bahr RD; O'Connor CM; Lowry DR; Gurbel PA
Cardiology; 1998 Jul; 90(1):37-42. PubMed ID: 9693169
[TBL] [Abstract][Full Text] [Related]
6. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.
Coulter SA; Cannon CP; Ault KA; Antman EM; Van de Werf F; Adgey AA; Gibson CM; Giugliano RP; Mascelli MA; Scherer J; Barnathan ES; Braunwald E; Kleiman NS
Circulation; 2000 Jun; 101(23):2690-5. PubMed ID: 10851205
[TBL] [Abstract][Full Text] [Related]
7. Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy.
Serebruany VL; Malinin AI; Callahan KP; Binbrek A; Van De Werf F; Alexander JH; Granger CB; Gurbel PA;
Am Heart J; 2003 Apr; 145(4):636-42. PubMed ID: 12679759
[TBL] [Abstract][Full Text] [Related]
8. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
Nordt TK; Moser M; Kohler B; Ruef J; Peter K; Kübler W; Bode C
Thromb Haemost; 1998 Dec; 80(6):881-6. PubMed ID: 9869154
[TBL] [Abstract][Full Text] [Related]
9. Increased baseline levels of platelet P-selectin, and platelet-endothelial cell adhesion molecule-1 in patients with acute myocardial infarction as predictors of unsuccessful thrombolysis.
Gurbel PA; Serebruany VL; Shustov AR; Dalesandro M; Gumbs CI; Grablutz LB; Bahr RD; Ohman EM; Topol EJ
Coron Artery Dis; 1998; 9(7):451-6. PubMed ID: 9822864
[TBL] [Abstract][Full Text] [Related]
10. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase.
Moser M; Nordt T; Peter K; Ruef J; Kohler B; Schmittner M; Smalling R; Kübler W; Bode C
Circulation; 1999 Nov; 100(18):1858-64. PubMed ID: 10545429
[TBL] [Abstract][Full Text] [Related]
11. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy.
Moshfegh K; Redondo M; Julmy F; Wuillemin WA; Gebauer MU; Haeberli A; Meyer BJ
J Am Coll Cardiol; 2000 Sep; 36(3):699-705. PubMed ID: 10987587
[TBL] [Abstract][Full Text] [Related]
12. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine.
Peter K; Kohler B; Straub A; Ruef J; Moser M; Nordt T; Olschewski M; Ohman ME; Kübler W; Bode C
Circulation; 2000 Sep; 102(13):1490-6. PubMed ID: 11004138
[TBL] [Abstract][Full Text] [Related]
13. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.
Ohman EM; Kleiman NS; Gacioch G; Worley SJ; Navetta FI; Talley JD; Anderson HV; Ellis SG; Cohen MD; Spriggs D; Miller M; Kereiakes D; Yakubov S; Kitt MM; Sigmon KN; Califf RM; Krucoff MW; Topol EJ
Circulation; 1997 Feb; 95(4):846-54. PubMed ID: 9054741
[TBL] [Abstract][Full Text] [Related]
14. Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?
Hermann A; Dzialowski I; Koch R; Gahn G
J Neurol Sci; 2009 Sep; 284(1-2):155-7. PubMed ID: 19473668
[TBL] [Abstract][Full Text] [Related]
15. Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction.
Serebruany VL; Gurbel PA
Arterioscler Thromb Vasc Biol; 1999 Jan; 19(1):153-8. PubMed ID: 9888878
[TBL] [Abstract][Full Text] [Related]
16. Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators.
Aylward PE; Wilcox RG; Horgan JH; White HD; Granger CB; Califf RM; Topol EJ
Ann Intern Med; 1996 Dec; 125(11):891-900. PubMed ID: 8967669
[TBL] [Abstract][Full Text] [Related]
17. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
[TBL] [Abstract][Full Text] [Related]
18. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C
Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148
[TBL] [Abstract][Full Text] [Related]
19. Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease for the Roxifiban Oral Compound Kinetics Evaluation Trial-I (ROCKET-I Platelet Substudy).
Serebruany VL; Malinin AI; O'connor CM; Gurbel PA;
Am Heart J; 2003 Jul; 146(1):91-8. PubMed ID: 12851613
[TBL] [Abstract][Full Text] [Related]
20. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction.
Parise P; Hauert J; Iorio A; Callegari P; Agnelli G
J Lab Clin Med; 1995 Feb; 125(2):212-21. PubMed ID: 7531212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
